Today: 11 June 2026
Salesforce stock slides 4% as 2026 opens — here’s what’s driving CRM and what investors watch next
3 January 2026
2 mins read

Salesforce stock slides 4% as 2026 opens — here’s what’s driving CRM and what investors watch next

NEW YORK, Jan 3, 2026, 10:35 ET — Market closed

  • Salesforce shares fell 4.26% in the last session, underperforming a firmer Dow.
  • Tech leadership rotated, with chips lifting the market while several megacap names sagged.
  • Focus turns to U.S. jobs and inflation data next week, then Salesforce earnings later this quarter.

Salesforce, Inc. shares closed down 4.26% on Friday at $253.62, their first regular-session finish of 2026, after trading between $252.48 and $265.38. The stock is about 31% below its 52-week high of $367.09.

The move matters now because Salesforce is a bellwether for enterprise software demand, and investors are starting the year debating how quickly corporate buyers will translate “AI” features into incremental spending. Salesforce has been treated as an AI-linked large-cap software name, leaving it sensitive to shifts in risk appetite and valuations.

U.S. stocks started 2026 on an uneven footing, with the Dow and S&P 500 ending higher while the Nasdaq was little changed, helped by a rally in chipmakers even as several megacap tech names fell. “Investors might be a little bit more conscious about some of the valuations that they’re paying for some of the AI plays,” Joe Mazzola, head of trading and derivatives strategist at Charles Schwab, told Reuters. Reuters

Within enterprise software, peers were mixed: ServiceNow fell 3.75% and Oracle gained 0.41% on Friday, market data showed, leaving Salesforce among the weaker names in the group.

Salesforce’s slide also extended a rough 12 months for the stock, which has lagged its prior peak even as investors chased pockets of the tech market that benefited from the chip rally. The company remains one of the largest U.S. software companies by market value and a heavyweight in major indexes.

Investors have been weighing Salesforce’s AI narrative against a still-tight spend environment for big corporate software budgets, where renewals and expansions can be sensitive to pricing and project timelines. That makes macro-driven valuation swings matter more than usual for the stock.

In early December, Salesforce raised its fiscal 2026 revenue and adjusted earnings forecasts, citing adoption of its AI software, including Agentforce. The company projected fiscal 2026 revenue of $41.45 billion to $41.55 billion and adjusted earnings per share of $11.75 to $11.77, Reuters reported at the time.

For Salesforce bulls, the debate is whether AI tools drive new demand or mainly shift existing budgets within customer IT spend. A key item investors track is current remaining performance obligation (cRPO), a measure of contracted revenue not yet recognized.

Before the next session, attention turns to U.S. economic data that can reset rate expectations — and, by extension, the valuation investors are willing to pay for software earnings. The jobs report due Jan. 9 and consumer price data due Jan. 13 sit at the top of the calendar, Reuters reported.

Traders will also monitor early-quarter positioning as the market moves from holiday-thin trading into a busier January, including headline risk around tariffs and policy expectations. Software stocks, which are often priced on future growth, tend to react when the outlook for interest rates shifts.

For Salesforce, the next major catalyst is its fiscal fourth-quarter earnings report. Analysts expect the company to report around Feb. 25, according to Public.com’s earnings calendar.

Beyond headline revenue and profit, investors will be watching for signs that AI-related products are lifting bookings and margins, and whether management reiterates or adjusts its full-year targets. On the chart, Friday’s low around $252 is an immediate support area, with the 52-week low of $221.96 the next level traders will watch if selling resumes.

Stock Market Today

  • AMD Stock Price Forecast: Analyst Lowers Target Amid AI Market Caution
    June 11, 2026, 11:00 AM EDT. Shares of Advanced Micro Devices (AMD) have surged 111% year-to-date, driven by investor optimism over its expanding role in the artificial intelligence (AI) sector. Despite the strong performance, a prominent AI-focused analyst has trimmed the price target for AMD, signaling caution about the chipmaker's near-term prospects. The analyst cited concerns over competitive pressures and potential market saturation. AMD's growth is largely tied to its ability to capture demand in AI computing, a fast-evolving field requiring specialized semiconductor technology. Investors are weighing the company's robust sales against risks from supply chain constraints and intensifying industry competition.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Markets brace for Monday after U.S. strike on Venezuela: oil, stocks and safe-haven demand in focus
Previous Story

Markets brace for Monday after U.S. strike on Venezuela: oil, stocks and safe-haven demand in focus

Quantum computing stocks surge to start 2026: D-Wave, Rigetti, IonQ lead — what investors watch next
Next Story

Quantum computing stocks surge to start 2026: D-Wave, Rigetti, IonQ lead — what investors watch next

Go toTop